Invesco’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $46.9M | Buy |
356,009
+12,588
| +4% | +$1.67M | ﹤0.01% | 1095 |
|
|
2025
Q4 | $48.7M | Buy |
343,421
+19,810
| +6% | +$2.87M | ﹤0.01% | 1098 |
|
|
2025
Q3 | $45.4M | Buy |
323,611
+34,366
| +12% | +$4.66M | 0.01% | 1120 |
|
|
2025
Q2 | $36.4M | Sell |
289,245
-278,075
| -49% | -$31.9M | 0.01% | 1190 |
|
|
2025
Q1 | $62.7M | Sell |
567,320
-382,192
| -40% | -$48.4M | 0.01% | 948 |
|
|
2024
Q4 | $130M | Buy |
949,512
+74,847
| +9% | +$9.26M | 0.02% | 734 |
|
|
2024
Q3 | $101M | Sell |
874,665
-383,439
| -30% | -$52.6M | 0.02% | 796 |
|
|
2024
Q2 | $173M | Buy |
1,258,104
+121,162
| +11% | +$16.6M | 0.04% | 609 |
|
|
2024
Q1 | $157M | Buy |
1,136,942
+463,134
| +69% | +$63.3M | 0.03% | 662 |
|
|
2023
Q4 | $88.8M | Buy |
673,808
+287,693
| +75% | +$33.1M | 0.02% | 795 |
|
|
2023
Q3 | $43.4M | Sell |
386,115
-176,245
| -31% | -$18.6M | 0.01% | 1019 |
|
|
2023
Q2 | $53M | Sell |
562,360
-13,914
| -2% | -$1.36M | 0.01% | 923 |
|
|
2023
Q1 | $58.3M | Sell |
576,274
-851,005
| -60% | -$88.6M | 0.02% | 884 |
|
|
2022
Q4 | $170M | Buy |
1,427,279
+521,568
| +58% | +$61.1M | 0.05% | 525 |
|
|
2022
Q3 | $96.2M | Buy |
905,711
+635,394
| +235% | +$64.5M | 0.03% | 679 |
|
|
2022
Q2 | $26.4M | Buy |
270,317
+18,452
| +7% | +$1.7M | 0.01% | 1216 |
|
|
2022
Q1 | $23.6M | Sell |
251,865
-29,253
| -10% | -$2.48M | 0.01% | 1407 |
|
|
2021
Q4 | $23.9M | Sell |
281,118
-46,693
| -14% | -$4.3M | 0.01% | 1444 |
|
|
2021
Q3 | $31.4M | Sell |
327,811
-766,088
| -70% | -$72.4M | 0.01% | 1273 |
|
|
2021
Q2 | $106M | Buy |
1,093,899
+6,534
| +0.6% | +$626K | 0.03% | 813 |
|
|
2021
Q1 | $106M | Buy |
1,087,365
+4,224
| +0.4% | +$443K | 0.03% | 774 |
|
|
2020
Q4 | $104M | Sell |
1,083,141
-650,332
| -38% | -$62.8M | 0.03% | 710 |
|
|
2020
Q3 | $167M | Sell |
1,733,473
-219,836
| -11% | -$25.4M | 0.06% | 424 |
|
|
2020
Q2 | $238M | Buy |
1,953,309
+959,127
| +96% | +$106M | 0.09% | 278 |
|
|
2020
Q1 | $86M | Sell |
994,182
-124,255
| -11% | -$12.2M | 0.04% | 562 |
|
|
2019
Q4 | $120M | Sell |
1,118,437
-204,879
| -15% | -$21.5M | 0.04% | 578 |
|
|
2019
Q3 | $119M | Buy |
1,323,316
+45,004
| +4% | +$4.2M | 0.03% | 595 |
|
|
2019
Q2 | $108M | Sell |
1,278,312
-644,606
| -34% | -$52.9M | 0.03% | 649 |
|
|
2019
Q1 | $169M | Sell |
1,922,918
-205,944
| -10% | -$17.2M | 0.06% | 379 |
|
|
2018
Q4 | $152M | Sell |
2,128,862
-4,180
| -0.2% | -$400K | 0.06% | 361 |
|
|
2018
Q3 | $262M | Buy |
2,133,042
+58,489
| +3% | +$6.64M | 0.08% | 255 |
|
|
2018
Q2 | $204M | Sell |
2,074,553
-297,902
| -13% | -$26.7M | 0.07% | 317 |
|
|
2018
Q1 | $197M | Sell |
2,372,455
-352,969
| -13% | -$29.8M | 0.07% | 286 |
|
|
2017
Q4 | $211M | Sell |
2,725,424
-224,444
| -8% | -$15.3M | 0.08% | 288 |
|
|
2017
Q3 | $181M | Sell |
2,949,868
-6,720
| -0.2% | -$355K | 0.07% | 325 |
|
|
2017
Q2 | $136M | Buy |
2,956,588
+235,524
| +9% | +$11.4M | 0.04% | 405 |
|
|
2017
Q1 | $118M | Sell |
2,721,064
-60,359
| -2% | -$2.59M | 0.04% | 448 |
|
|
2016
Q4 | $108M | Buy |
2,781,423
+184,782
| +7% | +$8.36M | 0.04% | 481 |
|
|
2016
Q3 | $131M | Buy |
2,596,641
+992,680
| +62% | +$49.4M | 0.05% | 418 |
|
|
2016
Q2 | $72.9M | Sell |
1,603,961
-778,940
| -33% | -$35.9M | 0.03% | 600 |
|
|
2016
Q1 | $94.2M | Buy |
2,382,901
+435,270
| +22% | +$17.3M | 0.04% | 524 |
|
|
2015
Q4 | $110M | Sell |
1,947,631
-236,689
| -11% | -$12M | 0.04% | 464 |
|
|
2015
Q3 | $86.9M | Buy |
2,184,320
+118,246
| +6% | +$5.72M | 0.04% | 527 |
|
|
2015
Q2 | $98.7M | Buy |
2,066,074
+228,248
| +12% | +$9.68M | 0.04% | 515 |
|
|
2015
Q1 | $73M | Buy |
1,837,826
+1,686,656
| +1,116% | +$60.3M | 0.03% | 631 |
|
|
2014
Q4 | $3.38M | Buy |
151,170
+150,480
| +21,809% | +$2.85M | ﹤0.01% | 2185 |
|
|
2014
Q3 | $11K | Buy |
690
+3
| +0.4% | +$45 | ﹤0.01% | 4024 |
|
|
2014
Q2 | $10K | Hold |
687
| – | – | ﹤0.01% | 4015 |
|
|
2014
Q1 | $11K | Sell |
687
-813,369
| -100% | -$13.9M | ﹤0.01% | 4026 |
|
|
2013
Q4 | $7.6M | Buy |
814,056
+423,110
| +108% | +$4.13M | ﹤0.01% | 1727 |
|
|
2013
Q3 | $4.42M | Sell |
390,946
-214
| -0.1% | -$2.94K | ﹤0.01% | 2013 |
|
|
2013
Q2 | $5.23M | Buy |
+391,160
| New | +$4.81M | ﹤0.01% | 1820 |
|
Other funds holding NBIX
VPM
VCM
Invesco's NBIX Position: Q1 2026 in Review
Invesco increased its Neurocrine Biosciences (NBIX) stake by 3.7% in Q1 2026, buying an estimated $1.67M and bringing the position to 356,009 shares worth $46.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1095.
Invesco first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $262M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Invesco held 356,009 shares of Neurocrine Biosciences worth $46.9M as of Q1 2026.
- Invesco bought 12,588 Neurocrine Biosciences shares in Q1 2026, an estimated $1.67M.
- Neurocrine Biosciences made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1095 holding.
- Invesco first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Invesco's Neurocrine Biosciences position peaked at $262M in Q3 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.